Article archive / June 1, 2014
Originally published: . Volume 5, No. 10. Source pages: 9.
New Orleans neuropsychologist, Dr. Susan Andrews, has teamed up as the co- investigator with Dr. Paul Harch, an LSU Medical School hyperbaric medicine physician and the primary investigator for a study of low- pressure hyperbaric oxygen therapy (HBOT) for persistent post-concussion syndrome and traumatic brain injury.
The study is funded by the Army and will measure the effect of HBOT on persistent post concussion syndrome in Iraq and Afghanistan veterans. It is starting this month at Louisiana State University Health Sciences Center. The study is open for patient referrals to participate and is limited to 50 subjects.
“Obviously, the long-term goal is to help the vets,” Andrews told the Times. “But another major goal is to evaluate the effectiveness of HBOT for persistent post-concussion syndrome under solid experimental conditions. My mom did HBOT after her stroke and it made a world of difference. I also did HBOT after a minor head trauma,” explained Andrews.
Hyperbaric oxygen therapy, or HBOT, is a treatment that has been shown in earlier studies to enhance the body's natural healing process. The patient inhales 100% oxygen while in a total body chamber. Atmospheric pressure is increased and controlled, and the increased oxygen allows new blood vessels to grow more rapidly into the affected areas, along with other benefits.
Andrews has collaborated with Harch in the two previous studies. They published, along with a number of coauthors, “A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress Disorder,” in the Journal of Neurotrauma, January 2012.
Significant improvements were reported in full scale IQ (14.8 points), in Delayed Memory and Working Memory, on the Stroop Test, TOVA Impulsivity and Variability, depression, anxiety, quality of life measures and other factors. Funded by a host of donors, phase I and II studies also included confirmation using pre and post SPECT scans, made popular by Daniel Amen, who was also part of the research team.
“Phase I and II included SPECT imaging,” Andrews explained to the Times. “We cannot afford imaging in this last phase. The neuropsychological measures are the primary outcome battery.” Drs. Harch and Andrews have developed and tested their battery over the years, she explained.
“I have been working with Dr. Harch for 25 years. I met him when he was invited to talk about HBOT to a small group of local neuropsychologists. We connected and have worked together on projects over the years. I was even privileged to go to Washington with him and Marty Hoffmann, former Secretary of the Army, to meet with the FDA in the run up to this final phase of the study.”
The study is fully funded through a congressional appropriation to Dr. Harch, the principal investigator, and LSU Health Sciences Center. It is administered by the U.S. Army Medical Research and Material Command (USARMRMC). Oklahoma State University School of Medicine and Hyperbaric Medicine Department will be a second site.
“My role as co-investigator,” said Andrews, “is to do the pre, post and post-post testing,” said Andrews. “I will be blind to group membership of the subjects. I helped to write the proposals and have participated in almost all parts of the project to date.”
The purpose of the current study is to determine if one course (40) of hyperbaric oxygen treatments (HBOTs) can help, worsen, or have no effect on subjects with chronic mild traumatic brain injury (mTBI)/persistent post-concussion syndrome (PPCS) compared to a control group receiving maintenance medication and/or counseling, according to the announcement.
Also, an attractive feature of this study is a crossover design which ensures that all participants will receive HBOT. In addition, the study will be open to both civilian and military patients and inclusive of multiple different types and causes of closed-head traumatic brain injury: blunt, blast, falls, vehicular accidents, assault, etc., the researchers noted.
The research team is looking for referrals of possible study candidates from psychologists and behavioral health professionals’ practices. For more information or questions about criteria for inclusion in the study, Cara Rowe, MSW, CCRP, research coordinator can be reached at 504-427-5632.
A complete description of the study and inclusion and exclusion criteria are posted on http://clinicaltrials.gov and http://www.hbo ttbistudy.org.
A photo from the U.S. Navy showing divers using Hyperbaric Oxygen Therapy or HBOT. A new Phase III study is being announced by Dr. Paul Harch, Dr. Susan Andrews, and Cara Rowe at LSUHSC. Dr. Susan Andrews presenting on music therapy at the Louisiana Psychological Association convention last year. She is co-investigator in a new study for HBOT.
This article is part of a historical newspaper archive. Read the original issue for its original layout, photographs and graphics.